Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMaze Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.73 | -$0.72 | -$0.72 |
| Q2 2025 | 3 | -$1.22 | -$0.53 | -$0.84 |
| Q3 2025 | 4 | -$0.77 | -$0.63 | -$0.71 |
| Q4 2025 | 5 | -$0.75 | -$0.67 | -$0.70 |
| Q1 2026 | 4 | -$0.79 | -$0.69 | -$0.75 |
| Q2 2026 | 1 | -$0.77 | -$0.77 | -$0.77 |
| Q3 2026 | 1 | -$0.77 | -$0.77 | -$0.77 |
| Q4 2026 | 1 | -$0.81 | -$0.81 | -$0.81 |
Maze Therapeutics, Inc. Earnings Date And Information
Maze Therapeutics, Inc. last posted its earnings results on Thursday, November 6th, 2025. The company reported $-0.66 earnings per share for the quarter, topping analysts' consensus estimates of $-0.74 by $0.08. The company had revenue of 0 for the quarter and had revenue of 167.50 M for the year. Maze Therapeutics, Inc. has generated $0 earnings per share over the last year ($0.0778 diluted earnings per share) and currently has a price-to-earnings ratio of -13.94. Maze Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 30th, 2026 based on prior year's report dates.
Maze Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | -$0.74 | -$0.66 | 0.08 | $2.08 M | $0 |
| 08/12/2025 | Q2 2025 | -$0.79 | -$0.77 | 0.02 | $3.13 M | $0 |
| 05/14/2025 | Q1 2025 | -$0.76 | -$0.75 | 0.01 | $0 | $0 |
| 03/31/2025 | Q4 2024 | $0.45 | -$0.11 | -0.56 | $0 | $0 |
| 09/30/2024 | Q3 2024 | N/A | -$0.06 | N/A | N/A | $2.50 M |
| 06/30/2024 | Q2 2024 | N/A | $0.98 | N/A | N/A | $165.00 M |
| 03/31/2024 | Q1 2024 | N/A | -$0.74 | N/A | N/A | $0 |
| 12/31/2023 | Q4 2023 | N/A | -$0.61 | N/A | N/A | $0 |
| 09/30/2023 | Q3 2023 | N/A | -$0.57 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Maze Therapeutics, Inc. Earnings: FAQ's
Maze Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 30th, 2026 based offlast year's report dates.
In the previous quarter, Maze Therapeutics, Inc. (:MAZE) reported $-0.66 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.74 by $0.08.
The conference call for Maze Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Maze Therapeutics, Inc.'s latest earnings report can be read online.
Maze Therapeutics, Inc. (:MAZE) has a recorded annual revenue of $167.50 M.
Maze Therapeutics, Inc. (:MAZE) has a recorded net income of $52.23 M.Maze Therapeutics, Inc. has generated $0.0778 earnings per share over the last four quarters.
Maze Therapeutics, Inc. (:MAZE) has a price-to-earnings ratio of -13.94 and price/earnings-to-growth ratio is 0.39.